PlumX Metrics
Embed PlumX Metrics

Sunitinib in Patients with Metastatic Renal Cell Carcinoma with Favorable Risk: Be Aware of PD-L1 Expression

Medical sciences (Basel, Switzerland), ISSN: 2076-3271, Vol: 12, Issue: 3
2024
  • 0
    Citations
  • 0
    Usage
  • 2
    Captures
  • 1
    Mentions
  • 0
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

  • Captures
    2
  • Mentions
    1
    • Blog Mentions
      1
      • Blog
        1

Article Description

The treatment landscape for metastatic renal cell carcinoma (RCC) has advanced significantly with first-line immunotargeted therapy combinations. However, no statistically significant differences were observed in the cohort of patients with favorable risk and some oncologists continue to use sunitinib in these patients. PD-L1 expression has emerged as a negative prognostic factor in RCC, particularly in sunitinib-treated patients, where higher PD-L1 levels are linked to worse outcomes. This article discusses the potential risks associated with the use of sunitinib in PD-L1-positive patients.

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know